Stryker (NYSE:SYK) Stock Unloaded by Rep. Thomas H. Kean, Jr.

Key Points

• Rep. Thomas H. Kean Jr. sold between $1,001 and $15,000 of Stryker shares on September 30, along with several other stock sales and purchases disclosed in recent filings.
• Stryker’s latest quarterly results fell slightly short of expectations, with adjusted EPS of $3.52 versus $3.55 expected and revenue of $6.52 billion versus $6.62 billion. Revenue still grew 7.6% year over year.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and $355.04 average price target, although several firms recently lowered targets or downgraded the stock to Hold.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on September 30th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 9/30/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 9/23/2026.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 9/17/2026.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 9/17/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of MasTec NYSE: MTZ on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Amcor NYSE: AMCR on 8/10/2026.

Stryker Trading Up 5.1%

Shares of Stryker stock opened at $306.77 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The company's 50-day moving average price is $292.37 and its 200-day moving average price is $324.26. The company has a market cap of $117.67 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 1.96 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analysts' expectations of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.19 earnings per share. On average, equities analysts expect that Stryker Corporation will post 14.85 earnings per share for the current fiscal year.

Institutional Trading of Stryker

Hedge funds have recently made changes to their positions in the company. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter worth approximately $25,000. Kilter Group LLC bought a new stake in shares of Stryker during the second quarter worth approximately $25,000. Cornerstone Financial Management LLC raised its position in shares of Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after buying an additional 31 shares in the last quarter. Highland Investment Advisors LLC bought a new position in shares of Stryker in the 2nd quarter valued at $25,000. Finally, Compass Financial Management LLC bought a new stake in Stryker in the second quarter valued at approximately $27,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Johnson Rice lowered shares of Stryker to a "hold" rating in a research note on Friday. Citizens Jmp cut their price target on Stryker from $400.00 to $390.00 and set a "market outperform" rating for the company in a report on Friday. UBS Group assumed coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective for the company. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Stryker from $350.00 to $340.00 and set an "overweight" rating on the stock in a research report on Friday. Sixteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $355.04.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: JPMorgan lowered its price target from $350 to $340 but maintained an Overweight rating, implying roughly 11% potential upside from the referenced share price.
• Positive Sentiment: Barclays reaffirmed its Buy rating, signaling continued confidence in Stryker’s medical-device portfolio despite near-term estimate revisions. Barclays Reaffirms Their Buy Rating on Stryker
• Neutral Sentiment: Truist reaffirmed its Hold rating and reduced its target from $310 to $305, indicating limited near-term upside at the referenced price. Truist Reaffirms Hold Rating on Stryker
• Neutral Sentiment: Price-target reductions from Citizens JMP, Citigroup, TD Cowen and Barclays reflect analysts resetting expectations after Stryker’s third-quarter results and guidance. Barclays nevertheless retained its Buy view. Stryker Fair Value Falls After Analysts Reset Expectations
• Negative Sentiment: Canaccord Genuity Group downgraded Stryker to Hold, adding to concern about valuation and the company’s near-term earnings outlook.
• Negative Sentiment: The stock recently fell below its 50-day moving average after Stryker slightly missed quarterly earnings and revenue expectations, an indication that disappointing results remain an overhang for investors. Stryker Stock Breaks Below 50-Day Moving Average

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares of the company's stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.